Review paper
Advances in immunotherapy for hepatocellular carcinoma
Volume: 18, Issue: 8, Pages: 525 - 543
Published: Apr 13, 2021
Abstract
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy with checkpoint inhibitors has shown strong anti-tumour activity in a subset of patients and the combination of the anti-PDL1 antibody atezolizumab and the VEGF-neutralizing antibody...
Paper Details
Title
Advances in immunotherapy for hepatocellular carcinoma
Published Date
Apr 13, 2021
Volume
18
Issue
8
Pages
525 - 543